European Neuropsychopharmacology最新文献_第2页

Sex differences in schizophrenia-related mortality: A call for targeted interventions

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2025-03-07 DOI: 10.1016/j.euroneuro.2025.02.011

Javier Labad

引用次数: 0

Commentary on “Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia” by Solmi and colleagues

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2025-03-07 DOI: 10.1016/j.euroneuro.2025.02.006

Gonzalo Salazar de Pablo , Ana Catalan , Maria Rogdaki , Paola Dazzan

引用次数: 0

The promise and challenges of mHealth in psychiatry: Bridging the gap between potential and long-awaited implementation

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2025-03-06 DOI: 10.1016/j.euroneuro.2025.02.013

Mari Skoge , Diego Hidalgo-Mazzei

引用次数: 0

The role of esketamine in persistent long COVID with predominant psychiatric manifestations

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2025-02-27 DOI: 10.1016/j.euroneuro.2024.12.014

Ina Bozic , Dominik Ivkic , Lutz Reinfried , Jakob Donath , Clemens Schmidt , Samantha Graf , Patricia Handschuh , Markus Dold , Dietmar Winkler , Angela Naderi-Haiden , Nicole Praschak-Rieder , Dan Rujescu , Ana Weidenauer , Lucie Bartova

引用次数: 0

Measuring the clinical dimensions of negative symptoms through the Positive and Negative Syndrome Scale

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2025-02-27 DOI: 10.1016/j.euroneuro.2024.12.016

Noham Wolpe , Andrea Perrottelli , Luigi Giuliani , Zixu Yang , Gurpreet Rekhi , Peter B. Jones , Miquel Bernardo , Maria Paz Garcia-Portilla , Stefan Kaiser , Gabriel Robert , Phillipe Robert , Anna Mane , Silvana Galderisi , Jimmy Lee , Armida Mucci , Emilio Fernandez-Egea

{"title":"Measuring the clinical dimensions of negative symptoms through the Positive and Negative Syndrome Scale","authors":"Noham Wolpe , Andrea Perrottelli , Luigi Giuliani , Zixu Yang , Gurpreet Rekhi , Peter B. Jones , Miquel Bernardo , Maria Paz Garcia-Portilla , Stefan Kaiser , Gabriel Robert , Phillipe Robert , Anna Mane , Silvana Galderisi , Jimmy Lee , Armida Mucci , Emilio Fernandez-Egea","doi":"10.1016/j.euroneuro.2024.12.016","DOIUrl":"10.1016/j.euroneuro.2024.12.016","url":null,"abstract":"<div><div>The negative symptoms of schizophrenia can determine functional outcome in patients. Despite its clinical significance, no treatment exists to date, as numerous pharmacological and non-pharmacological clinical trials have failed to demonstrate efficacy. Many of these trials evaluated negative symptoms as a single clinical construct. However, consistent evidence in the past two decades has found that negative symptoms constitute at least two independent clinical dimensions, namely deficits in motivation and pleasure (MAP) and in emotional expression (EXP). These dimensions are best evaluated using new assessment tools, such as the Brief Negative Symptom Scale (BNSS). However, older assessment tools, and particularly the Positive and Negative Syndrome Scale (PANSS), remain widely used in past and current research. Here, we sought to predict BNSS MAP and EXP dimensions from the PANSS. Using complementary modelling approaches across three heterogeneous, multi-centre, multi-culture patient samples (<em>n</em> = 1241 patients, 1846 observations), we show that MAP can be estimated (43–60 % variance explained) predominantly using N2 and N4. Moreover, EXP can be estimated predominantly using the two PANSS items N1 and N6 (55–81 % variance explained across models and samples). Additionally, PANSS-derived MAP shows associations with functioning similar to those measured by the BNSS MAP dimension. Together, our results suggest that while EXP can be reliably estimated from PANSS, MAP cannot be consistently estimated from PANSS across samples and cultures. This warrants caution when using the PANSS to estimate MAP and emphasises the need for using the newer assessment tools for negative symptoms.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 68-76"},"PeriodicalIF":6.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lack of transparency on baseline pharmacological treatments in Clinical High-Risk for psychosis (CHR-P) may degrade precision: A systematic review and meta-analysis

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2025-02-21 DOI: 10.1016/j.euroneuro.2025.01.007

Andrea Raballo , Michele Poletti , Antonio Preti

{"title":"Lack of transparency on baseline pharmacological treatments in Clinical High-Risk for psychosis (CHR-P) may degrade precision: A systematic review and meta-analysis","authors":"Andrea Raballo , Michele Poletti , Antonio Preti","doi":"10.1016/j.euroneuro.2025.01.007","DOIUrl":"10.1016/j.euroneuro.2025.01.007","url":null,"abstract":"<div><div>The field of Clinical High-Risk for Psychosis (CHR-P) is a dynamic area within contemporary psychiatry and serves as a crucial testing ground for precision prognostic models. Nonetheless, some foundational aspects remain inadequately conceptualized and consequently not transparently reported, such as baseline pharmacotherapy. A systematic review and meta-analysis were conducted by searching the MEDLINE and Cochrane Library databases for studies published up to August 31, 2024. Eligible studies included CHR-P samples, reported numeric data on outcomes at follow-up, and examined the transition to psychosis as an outcome. Data extraction adhered to PRISMA guidelines, focusing on baseline pharmacological exposure to antipsychotics, antidepressants, benzodiazepines, and mood stabilizers. A total of 95 studies were analyzed. The majority of studies (96.8 %) explicitly stated whether baseline exposure to antipsychotics was allowed as part of the inclusion criteria. However, actual baseline exposure to antipsychotics was quantified in only 60 % of these studies. Exposure to non-antipsychotic psychoactive therapies was reported in only a fraction of the studies (36.8 % for antidepressants, 16.8 % for benzodiazepines, and 14.7 % for mood stabilizers). In CHR-P longitudinal studies, the meta-analytic proportions of self-disclosed baseline pharmacological exposure ranged from 23.5 % to 24.5 % for antipsychotics, 28.5 % to 30.6 % for antidepressants, 11.2 % to 14.6 % for benzodiazepines, and 5.6 % to 5.9 % for mood stabilizers.</div><div>Overall, a non negligible fraction of CHR-P participants is already under psychoactive pharmacological treatment at enrollment. The lack of consistent transparency in this respect may limit the effectiveness of prognostic models. Improved reporting practices are necessary to enhance precision in preventive psychiatry.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 58-65"},"PeriodicalIF":6.1,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143453098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The cumulative production and conjugation of steroid hormones during pregnancy predict postpartum depressive mood

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2025-02-21 DOI: 10.1016/j.euroneuro.2025.02.004

Anna Soler , Francisco Madrid-Gambín , Olha Khymenets , Camila Servin-Barthet , Magdalena Martínez-García , Maria Paternina-Die , Montserrat Montané-García , Clara Pretus , Susana Carmona , Óscar J. Pozo , Oscar Vilarroya

引用次数: 0

On the potential of xanomeline-trospium chloride for schizophrenia and beyond

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2025-02-16 DOI: 10.1016/j.euroneuro.2025.02.002

Nicholas Fabiano , Stanley Wong , Carl Zhou , Christoph U. Correll , Mikkel Højlund , Marco Solmi

引用次数: 0

Artificial intelligence in healthcare: Revolution or unfulfilled promise?

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2025-02-16 DOI: 10.1016/j.euroneuro.2025.01.006

Gerard Anmella , Enrique Baca-García

引用次数: 0

Prescription sequences in bipolar disorder – A nationwide Danish register-based study of 19,927 individuals followed for 10 years

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2025-02-16 DOI: 10.1016/j.euroneuro.2025.01.008

Anders Jorgensen , Mathilde Marie Brünnich Sloth , Emma Neble Larsen , Merete Osler , Lars Vedel Kessing

{"title":"Prescription sequences in bipolar disorder – A nationwide Danish register-based study of 19,927 individuals followed for 10 years","authors":"Anders Jorgensen , Mathilde Marie Brünnich Sloth , Emma Neble Larsen , Merete Osler , Lars Vedel Kessing","doi":"10.1016/j.euroneuro.2025.01.008","DOIUrl":"10.1016/j.euroneuro.2025.01.008","url":null,"abstract":"<div><div>Evidence-based use of pharmacological interventions in bipolar disorder is of paramount clinical importance. We aimed to uncover precription sequences in a large cohort of patients from the first diagnosis of bipolar disorder. Using Danish nationwide registers, we identified individuals with a first-time hospital diagnosis of bipolar disorder between January 1<sup>st</sup>, 2001, and December 31<sup>st</sup>, 2016. Redemeed prescriptions of litihum, anticonvulsants, antipsychotics, and antidepressants from five years before to five years after diagnosis were retreived. The data were analysed with descriptive statistics, sunburst plots, and Cox proportioal hazard models. The full study population consisted of 19,927 individuals. Before diagnosis, antidepressants were the predominantly prescribed group (46.9 % as first drug). After diagnosis, a major trend towards mood stabilising strategies was observed. although only 18.7 % received lithiumas first prescription. In analyses stratified for illness phase, lithium was more frequently prescribed as first drug after depression than after hypomania/mania, in which antidepressants were used as first drug in 10-15 % of the cases. Treatment sequences were highly heterogeneous (2,459 distinct sequences for the 19,927 individuals under investigation). Lithium appeared to carry the overall highest risk of treatment shift. We conclude that in accordance with national and international guidelines, a diagnosis of bipolar disorder leads to a relevant change of treatment strategy towards mood stabilising drugs. However, lithium continues to be underused;antidepressants probably used too frequently, and treatment sequences are highly heterogeneous and not adjusted according to illness phase. These results point to a potential for optimising the real-world pharmacological management of bipolar disorder.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 51-57"},"PeriodicalIF":6.1,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0